India, April 26 -- Medtronic plc (MDT) said that it received U.S. Food and Drug Administration approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement.
The lead connects to an implantable defibrillator, and treats potentially life threatening ventricular tachyarrhythmias, ventricular fibrillation (VT/VF) and bradyarrhythmias. The OmniaSecure lead represents a meaningful innovation in electrophysiology, and is indicated for stimulation in the right ventricle for adults and adolescent pediatric patients ages 12 ...